| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Stroke | 59 | 2022 | 2161 | 3.920 |
Why?
|
| Research Design | 28 | 2019 | 729 | 3.350 |
Why?
|
| Cerebral Hemorrhage | 23 | 2022 | 198 | 2.960 |
Why?
|
| Tissue Plasminogen Activator | 27 | 2017 | 296 | 2.690 |
Why?
|
| Randomized Controlled Trials as Topic | 13 | 2016 | 929 | 2.650 |
Why?
|
| Antihypertensive Agents | 17 | 2022 | 497 | 2.130 |
Why?
|
| Endovascular Procedures | 18 | 2019 | 366 | 2.040 |
Why?
|
| Clinical Trials as Topic | 19 | 2018 | 848 | 1.930 |
Why?
|
| Data Interpretation, Statistical | 12 | 2018 | 329 | 1.910 |
Why?
|
| Random Allocation | 5 | 2015 | 442 | 1.760 |
Why?
|
| Clinical Trials, Phase III as Topic | 8 | 2018 | 84 | 1.690 |
Why?
|
| Brain Ischemia | 22 | 2019 | 665 | 1.680 |
Why?
|
| Fibrinolytic Agents | 20 | 2018 | 377 | 1.530 |
Why?
|
| Nicardipine | 9 | 2021 | 21 | 1.380 |
Why?
|
| Treatment Outcome | 56 | 2022 | 7028 | 1.360 |
Why?
|
| Aspirin | 9 | 2019 | 295 | 1.350 |
Why?
|
| Platelet Aggregation Inhibitors | 10 | 2019 | 373 | 1.230 |
Why?
|
| Thrombolytic Therapy | 11 | 2017 | 233 | 1.220 |
Why?
|
| Ischemic Attack, Transient | 6 | 2019 | 167 | 1.130 |
Why?
|
| Hypertension | 11 | 2022 | 1531 | 0.920 |
Why?
|
| Bias | 7 | 2015 | 148 | 0.920 |
Why?
|
| Multicenter Studies as Topic | 4 | 2012 | 186 | 0.910 |
Why?
|
| Humans | 137 | 2022 | 68525 | 0.850 |
Why?
|
| Algorithms | 6 | 2015 | 1194 | 0.830 |
Why?
|
| Endpoint Determination | 4 | 2019 | 82 | 0.820 |
Why?
|
| Statistics as Topic | 5 | 2015 | 219 | 0.810 |
Why?
|
| Albumins | 6 | 2016 | 72 | 0.800 |
Why?
|
| Aged | 65 | 2021 | 14842 | 0.750 |
Why?
|
| Biostatistics | 2 | 2018 | 43 | 0.750 |
Why?
|
| Blood Pressure | 15 | 2022 | 1447 | 0.740 |
Why?
|
| Thrombectomy | 5 | 2018 | 238 | 0.730 |
Why?
|
| Middle Aged | 74 | 2022 | 21119 | 0.710 |
Why?
|
| Patient Selection | 7 | 2018 | 592 | 0.700 |
Why?
|
| Computer Simulation | 11 | 2016 | 705 | 0.640 |
Why?
|
| Progesterone | 5 | 2019 | 115 | 0.590 |
Why?
|
| Double-Blind Method | 20 | 2019 | 1737 | 0.590 |
Why?
|
| Neuroprotective Agents | 5 | 2019 | 317 | 0.590 |
Why?
|
| Clinical Trials, Phase II as Topic | 5 | 2012 | 58 | 0.590 |
Why?
|
| Female | 80 | 2022 | 38015 | 0.580 |
Why?
|
| Male | 76 | 2021 | 37281 | 0.570 |
Why?
|
| Brain Injuries, Traumatic | 4 | 2019 | 105 | 0.560 |
Why?
|
| Neuroimaging | 2 | 2015 | 122 | 0.540 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 2 | 2019 | 148 | 0.530 |
Why?
|
| Models, Statistical | 5 | 2012 | 446 | 0.520 |
Why?
|
| Drug Therapy, Combination | 10 | 2019 | 648 | 0.510 |
Why?
|
| Linear Models | 2 | 2015 | 521 | 0.500 |
Why?
|
| Severity of Illness Index | 11 | 2019 | 1851 | 0.500 |
Why?
|
| Quality of Life | 6 | 2018 | 1515 | 0.500 |
Why?
|
| Infusions, Intravenous | 12 | 2019 | 334 | 0.480 |
Why?
|
| Aged, 80 and over | 25 | 2019 | 4843 | 0.460 |
Why?
|
| Hematoma | 6 | 2022 | 47 | 0.460 |
Why?
|
| Clinical Trials Data Monitoring Committees | 2 | 2010 | 6 | 0.460 |
Why?
|
| Logistic Models | 5 | 2013 | 1419 | 0.460 |
Why?
|
| Serum Albumin | 6 | 2013 | 104 | 0.460 |
Why?
|
| Ticlopidine | 5 | 2018 | 118 | 0.450 |
Why?
|
| Sample Size | 7 | 2012 | 79 | 0.450 |
Why?
|
| Adult | 45 | 2019 | 21375 | 0.390 |
Why?
|
| Probability | 4 | 2015 | 244 | 0.390 |
Why?
|
| Deferoxamine | 3 | 2019 | 45 | 0.390 |
Why?
|
| Cerebral Angiography | 7 | 2018 | 151 | 0.390 |
Why?
|
| Secondary Prevention | 8 | 2019 | 291 | 0.380 |
Why?
|
| Acute Disease | 8 | 2019 | 658 | 0.380 |
Why?
|
| Information Management | 1 | 2010 | 23 | 0.380 |
Why?
|
| Adverse Drug Reaction Reporting Systems | 1 | 2010 | 41 | 0.370 |
Why?
|
| Glasgow Coma Scale | 5 | 2019 | 65 | 0.370 |
Why?
|
| Internet | 2 | 2010 | 390 | 0.360 |
Why?
|
| Parkinson Disease | 6 | 2011 | 272 | 0.360 |
Why?
|
| Emergency Medical Services | 4 | 2018 | 225 | 0.360 |
Why?
|
| Database Management Systems | 1 | 2009 | 25 | 0.360 |
Why?
|
| Young Adult | 16 | 2019 | 5708 | 0.360 |
Why?
|
| Family Practice | 3 | 2003 | 312 | 0.350 |
Why?
|
| Emergency Medicine | 1 | 2010 | 88 | 0.350 |
Why?
|
| Cerebral Revascularization | 3 | 2016 | 45 | 0.350 |
Why?
|
| Documentation | 1 | 2009 | 83 | 0.340 |
Why?
|
| Ischemia | 3 | 2019 | 229 | 0.340 |
Why?
|
| Intracranial Hemorrhages | 2 | 2019 | 80 | 0.340 |
Why?
|
| Tomography, X-Ray Computed | 9 | 2020 | 2323 | 0.340 |
Why?
|
| Follow-Up Studies | 12 | 2019 | 3256 | 0.320 |
Why?
|
| Data Collection | 1 | 2009 | 420 | 0.310 |
Why?
|
| Arterial Occlusive Diseases | 4 | 2016 | 134 | 0.310 |
Why?
|
| Markov Chains | 2 | 2018 | 133 | 0.310 |
Why?
|
| Critical Care | 3 | 2015 | 263 | 0.290 |
Why?
|
| United States | 19 | 2020 | 7335 | 0.290 |
Why?
|
| Time Factors | 12 | 2020 | 4655 | 0.290 |
Why?
|
| Reperfusion | 3 | 2016 | 78 | 0.290 |
Why?
|
| Nervous System | 1 | 2006 | 45 | 0.280 |
Why?
|
| Internship and Residency | 3 | 2003 | 596 | 0.280 |
Why?
|
| Benzoates | 4 | 2009 | 20 | 0.270 |
Why?
|
| Hemorrhage | 5 | 2019 | 328 | 0.270 |
Why?
|
| Prospective Studies | 15 | 2021 | 3702 | 0.270 |
Why?
|
| Disability Evaluation | 7 | 2020 | 298 | 0.260 |
Why?
|
| Benzimidazoles | 4 | 2009 | 128 | 0.250 |
Why?
|
| Medical Futility | 4 | 2019 | 31 | 0.250 |
Why?
|
| Recovery of Function | 3 | 2018 | 506 | 0.250 |
Why?
|
| National Institute of Neurological Disorders and Stroke (U.S.) | 3 | 2015 | 20 | 0.250 |
Why?
|
| Raynaud Disease | 3 | 1999 | 24 | 0.250 |
Why?
|
| Buspirone | 1 | 2004 | 36 | 0.240 |
Why?
|
| Survival Analysis | 4 | 2018 | 714 | 0.230 |
Why?
|
| Proportional Hazards Models | 5 | 2019 | 791 | 0.230 |
Why?
|
| Amyotrophic Lateral Sclerosis | 1 | 2004 | 98 | 0.230 |
Why?
|
| Anti-Anxiety Agents | 1 | 2004 | 107 | 0.230 |
Why?
|
| Anger | 1 | 2003 | 47 | 0.220 |
Why?
|
| Mechanical Thrombolysis | 2 | 2019 | 29 | 0.220 |
Why?
|
| Internationality | 2 | 2020 | 74 | 0.210 |
Why?
|
| Burnout, Professional | 1 | 2003 | 64 | 0.210 |
Why?
|
| Perfusion Imaging | 2 | 2018 | 27 | 0.200 |
Why?
|
| Dipyridamole | 3 | 2010 | 26 | 0.200 |
Why?
|
| Lorazepam | 2 | 2012 | 54 | 0.190 |
Why?
|
| Odds Ratio | 4 | 2013 | 880 | 0.190 |
Why?
|
| Anxiety Disorders | 1 | 2004 | 426 | 0.190 |
Why?
|
| Adolescent | 14 | 2017 | 8903 | 0.190 |
Why?
|
| Drug Administration Schedule | 5 | 2016 | 567 | 0.190 |
Why?
|
| Cerebral Intraventricular Hemorrhage | 1 | 2020 | 4 | 0.190 |
Why?
|
| Intubation, Intratracheal | 2 | 2018 | 99 | 0.180 |
Why?
|
| Status Epilepticus | 2 | 2012 | 74 | 0.180 |
Why?
|
| S100 Calcium Binding Protein beta Subunit | 1 | 2019 | 15 | 0.180 |
Why?
|
| Spectrin | 1 | 2019 | 17 | 0.180 |
Why?
|
| Ubiquitin Thiolesterase | 1 | 2019 | 23 | 0.180 |
Why?
|
| Anxiety | 1 | 2003 | 422 | 0.180 |
Why?
|
| Opioid-Related Disorders | 1 | 2004 | 298 | 0.180 |
Why?
|
| Attitude of Health Personnel | 1 | 2003 | 442 | 0.170 |
Why?
|
| Dental Plaque | 2 | 1999 | 14 | 0.170 |
Why?
|
| Gingivitis | 2 | 1999 | 16 | 0.170 |
Why?
|
| Disease Progression | 6 | 2020 | 1037 | 0.170 |
Why?
|
| Glial Fibrillary Acidic Protein | 1 | 2019 | 92 | 0.170 |
Why?
|
| Iron Chelating Agents | 1 | 2019 | 31 | 0.170 |
Why?
|
| Anticonvulsants | 2 | 2012 | 223 | 0.170 |
Why?
|
| Goals | 1 | 2019 | 65 | 0.170 |
Why?
|
| Sex Characteristics | 2 | 2020 | 295 | 0.170 |
Why?
|
| Carotid Artery, Internal | 2 | 2016 | 85 | 0.160 |
Why?
|
| Pyridones | 1 | 2018 | 40 | 0.160 |
Why?
|
| Dental Calculus | 1 | 1998 | 6 | 0.160 |
Why?
|
| Dental Devices, Home Care | 1 | 1998 | 17 | 0.160 |
Why?
|
| Gastrointestinal Hemorrhage | 2 | 2019 | 185 | 0.160 |
Why?
|
| Infarction, Middle Cerebral Artery | 2 | 2016 | 105 | 0.160 |
Why?
|
| Brain Edema | 3 | 2014 | 50 | 0.160 |
Why?
|
| Analysis of Variance | 4 | 2007 | 1039 | 0.160 |
Why?
|
| Cerebrovascular Disorders | 3 | 2016 | 182 | 0.160 |
Why?
|
| Cerebral Infarction | 2 | 2009 | 103 | 0.150 |
Why?
|
| Effect Modifier, Epidemiologic | 1 | 1997 | 8 | 0.150 |
Why?
|
| Rehabilitation Research | 1 | 2017 | 2 | 0.150 |
Why?
|
| Pyrazoles | 1 | 2018 | 190 | 0.150 |
Why?
|
| Pilot Projects | 7 | 2014 | 1341 | 0.150 |
Why?
|
| Cardiomyopathies | 1 | 2018 | 167 | 0.150 |
Why?
|
| Disease Management | 2 | 2015 | 248 | 0.140 |
Why?
|
| Prognosis | 9 | 2017 | 2093 | 0.140 |
Why?
|
| Cohort Studies | 6 | 2015 | 2356 | 0.140 |
Why?
|
| Monte Carlo Method | 3 | 2012 | 124 | 0.140 |
Why?
|
| Depression | 3 | 2004 | 942 | 0.140 |
Why?
|
| Risk | 6 | 2019 | 563 | 0.140 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 1998 | 782 | 0.140 |
Why?
|
| Statistics, Nonparametric | 3 | 2010 | 306 | 0.140 |
Why?
|
| Combined Modality Therapy | 5 | 2018 | 951 | 0.140 |
Why?
|
| Poisson Distribution | 1 | 2015 | 84 | 0.140 |
Why?
|
| Neurophysiological Monitoring | 1 | 2015 | 1 | 0.130 |
Why?
|
| Triiodobenzoic Acids | 1 | 2015 | 28 | 0.130 |
Why?
|
| Iopamidol | 1 | 2015 | 37 | 0.130 |
Why?
|
| Iohexol | 1 | 2015 | 82 | 0.130 |
Why?
|
| Information Systems | 2 | 2015 | 45 | 0.130 |
Why?
|
| Lymph Nodes | 3 | 2005 | 258 | 0.130 |
Why?
|
| Interleukin-1 | 3 | 1999 | 86 | 0.130 |
Why?
|
| Safety | 1 | 2015 | 145 | 0.130 |
Why?
|
| Neurologic Examination | 2 | 2011 | 107 | 0.130 |
Why?
|
| Propensity Score | 1 | 2014 | 116 | 0.130 |
Why?
|
| Cerebral Arterial Diseases | 1 | 2014 | 28 | 0.120 |
Why?
|
| Stroke Rehabilitation | 2 | 2017 | 334 | 0.120 |
Why?
|
| Cooperative Behavior | 1 | 2015 | 235 | 0.120 |
Why?
|
| Pulmonary Edema | 3 | 2015 | 37 | 0.120 |
Why?
|
| Health Care Costs | 1 | 2017 | 346 | 0.120 |
Why?
|
| Collateral Circulation | 1 | 2014 | 34 | 0.120 |
Why?
|
| Siderophores | 1 | 2013 | 16 | 0.120 |
Why?
|
| Anesthesia, General | 1 | 2014 | 86 | 0.120 |
Why?
|
| Alcohol Drinking | 2 | 1999 | 805 | 0.120 |
Why?
|
| Matched-Pair Analysis | 2 | 2003 | 25 | 0.120 |
Why?
|
| Multivariate Analysis | 3 | 2014 | 1046 | 0.120 |
Why?
|
| National Institutes of Health (U.S.) | 3 | 2019 | 109 | 0.110 |
Why?
|
| Hematoma, Subdural, Intracranial | 1 | 2012 | 2 | 0.110 |
Why?
|
| Numerical Analysis, Computer-Assisted | 1 | 2013 | 13 | 0.110 |
Why?
|
| Recombinant Proteins | 2 | 2014 | 742 | 0.110 |
Why?
|
| Diuretics | 3 | 2010 | 96 | 0.110 |
Why?
|
| Smoking | 3 | 1999 | 1449 | 0.110 |
Why?
|
| Blood Platelets | 1 | 2013 | 284 | 0.110 |
Why?
|
| Injections, Intramuscular | 1 | 2012 | 44 | 0.110 |
Why?
|
| Biomedical Research | 1 | 2015 | 310 | 0.110 |
Why?
|
| Midazolam | 1 | 2012 | 46 | 0.100 |
Why?
|
| Contrast Media | 1 | 2015 | 594 | 0.100 |
Why?
|
| Stochastic Processes | 1 | 2011 | 27 | 0.100 |
Why?
|
| Peptides | 1 | 2014 | 455 | 0.100 |
Why?
|
| Selection Bias | 1 | 2011 | 23 | 0.100 |
Why?
|
| Brain Injuries | 1 | 2014 | 268 | 0.100 |
Why?
|
| Sensitivity and Specificity | 6 | 2005 | 1753 | 0.100 |
Why?
|
| Survival Rate | 2 | 2011 | 1055 | 0.100 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2010 | 1745 | 0.100 |
Why?
|
| Area Under Curve | 1 | 2011 | 238 | 0.100 |
Why?
|
| Kaplan-Meier Estimate | 4 | 2019 | 536 | 0.100 |
Why?
|
| Nervous System Diseases | 1 | 2012 | 142 | 0.100 |
Why?
|
| Practice Guidelines as Topic | 1 | 2015 | 772 | 0.100 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 2 | 2008 | 201 | 0.100 |
Why?
|
| Intracranial Hemorrhage, Hypertensive | 1 | 2010 | 5 | 0.090 |
Why?
|
| Hyperglycemia | 1 | 2011 | 158 | 0.090 |
Why?
|
| Safety Management | 1 | 2010 | 73 | 0.090 |
Why?
|
| United States Food and Drug Administration | 1 | 2010 | 131 | 0.090 |
Why?
|
| Breast Neoplasms | 3 | 2005 | 1533 | 0.090 |
Why?
|
| Self Report | 1 | 2011 | 370 | 0.090 |
Why?
|
| Placebos | 2 | 2013 | 195 | 0.090 |
Why?
|
| Injections, Intravenous | 2 | 2006 | 215 | 0.090 |
Why?
|
| Acute Kidney Injury | 1 | 2012 | 232 | 0.090 |
Why?
|
| Japan | 3 | 2020 | 68 | 0.090 |
Why?
|
| Antiparkinson Agents | 2 | 2006 | 34 | 0.090 |
Why?
|
| Treatment Failure | 3 | 2016 | 216 | 0.080 |
Why?
|
| Reproducibility of Results | 5 | 2012 | 2077 | 0.080 |
Why?
|
| Periodontitis | 2 | 1999 | 47 | 0.080 |
Why?
|
| Blood Glucose | 1 | 2011 | 631 | 0.080 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 1 | 2008 | 95 | 0.080 |
Why?
|
| Ultrasonic Therapy | 1 | 2008 | 19 | 0.080 |
Why?
|
| Netherlands | 2 | 2019 | 68 | 0.080 |
Why?
|
| Benzenesulfonates | 1 | 2007 | 30 | 0.080 |
Why?
|
| Sphincter of Oddi | 2 | 1998 | 51 | 0.080 |
Why?
|
| Predictive Value of Tests | 4 | 2019 | 1465 | 0.080 |
Why?
|
| Risk Assessment | 3 | 2019 | 2004 | 0.080 |
Why?
|
| Glasgow Outcome Scale | 2 | 2019 | 15 | 0.080 |
Why?
|
| Ultrasonography, Interventional | 1 | 2008 | 119 | 0.080 |
Why?
|
| Biomarkers | 4 | 2019 | 1593 | 0.070 |
Why?
|
| Recurrence | 3 | 2018 | 948 | 0.070 |
Why?
|
| Ethics, Research | 1 | 2007 | 12 | 0.070 |
Why?
|
| Myocardial Ischemia | 1 | 2008 | 172 | 0.070 |
Why?
|
| Intracranial Embolism | 1 | 2006 | 25 | 0.070 |
Why?
|
| South Carolina | 4 | 2003 | 2750 | 0.070 |
Why?
|
| Length of Stay | 2 | 2017 | 780 | 0.070 |
Why?
|
| Brain | 2 | 2014 | 2175 | 0.070 |
Why?
|
| Hospitalization | 1 | 2011 | 977 | 0.070 |
Why?
|
| Pancreatitis | 2 | 1998 | 279 | 0.070 |
Why?
|
| Sentinel Lymph Node Biopsy | 1 | 2005 | 53 | 0.070 |
Why?
|
| Antioxidants | 1 | 2007 | 304 | 0.070 |
Why?
|
| Nonlinear Dynamics | 1 | 2005 | 55 | 0.060 |
Why?
|
| Dopamine Agents | 1 | 2005 | 56 | 0.060 |
Why?
|
| Cholangiopancreatography, Endoscopic Retrograde | 2 | 1998 | 348 | 0.060 |
Why?
|
| Radiopharmaceuticals | 1 | 2005 | 114 | 0.060 |
Why?
|
| Health Status | 2 | 1999 | 429 | 0.060 |
Why?
|
| Cognition | 1 | 2008 | 512 | 0.060 |
Why?
|
| Substantia Nigra | 1 | 2005 | 102 | 0.060 |
Why?
|
| Colonography, Computed Tomographic | 1 | 2004 | 23 | 0.060 |
Why?
|
| Epilepsy, Absence | 1 | 1983 | 3 | 0.060 |
Why?
|
| Cross-Sectional Studies | 3 | 1999 | 2264 | 0.060 |
Why?
|
| Monitoring, Physiologic | 2 | 2019 | 219 | 0.060 |
Why?
|
| Corpus Striatum | 1 | 2005 | 278 | 0.060 |
Why?
|
| Colonoscopy | 1 | 2004 | 156 | 0.060 |
Why?
|
| Cluster Analysis | 1 | 2003 | 218 | 0.060 |
Why?
|
| Neoplasm Invasiveness | 1 | 2004 | 369 | 0.060 |
Why?
|
| Psychological Tests | 1 | 2003 | 96 | 0.060 |
Why?
|
| Myocardial Infarction | 3 | 2018 | 807 | 0.060 |
Why?
|
| Canada | 2 | 2017 | 266 | 0.050 |
Why?
|
| Cardiovascular Diseases | 2 | 2008 | 938 | 0.050 |
Why?
|
| France | 2 | 1999 | 26 | 0.050 |
Why?
|
| Confidence Intervals | 3 | 2013 | 242 | 0.050 |
Why?
|
| Nursing Homes | 1 | 1981 | 54 | 0.050 |
Why?
|
| Dyspepsia | 1 | 2001 | 8 | 0.050 |
Why?
|
| Polymorphism, Genetic | 2 | 1999 | 301 | 0.050 |
Why?
|
| Age Factors | 3 | 2015 | 1860 | 0.050 |
Why?
|
| Educational Status | 2 | 1999 | 273 | 0.050 |
Why?
|
| Cost-Benefit Analysis | 2 | 2017 | 503 | 0.050 |
Why?
|
| Decision Making | 2 | 2015 | 410 | 0.050 |
Why?
|
| Taiwan | 1 | 2020 | 20 | 0.050 |
Why?
|
| Republic of Korea | 1 | 2020 | 23 | 0.050 |
Why?
|
| Germany | 1 | 2020 | 67 | 0.050 |
Why?
|
| Risk Factors | 5 | 2010 | 5719 | 0.050 |
Why?
|
| Patient Care Planning | 1 | 2020 | 108 | 0.050 |
Why?
|
| China | 1 | 2020 | 138 | 0.050 |
Why?
|
| Evidence-Based Medicine | 2 | 2015 | 438 | 0.050 |
Why?
|
| International Cooperation | 2 | 2012 | 88 | 0.050 |
Why?
|
| Endoscopy, Gastrointestinal | 1 | 2001 | 170 | 0.040 |
Why?
|
| Hematuria | 1 | 2019 | 24 | 0.040 |
Why?
|
| Comorbidity | 2 | 2014 | 1425 | 0.040 |
Why?
|
| Alopecia Areata | 1 | 1999 | 17 | 0.040 |
Why?
|
| Immunoglobulin kappa-Chains | 1 | 1999 | 30 | 0.040 |
Why?
|
| Coronary Disease | 2 | 1982 | 358 | 0.040 |
Why?
|
| Seasons | 1 | 1999 | 129 | 0.040 |
Why?
|
| Colorectal Neoplasms | 1 | 2004 | 560 | 0.040 |
Why?
|
| Clinical Protocols | 1 | 2019 | 172 | 0.040 |
Why?
|
| Oral Hygiene Index | 1 | 1998 | 2 | 0.040 |
Why?
|
| Dental Plaque Index | 1 | 1998 | 10 | 0.040 |
Why?
|
| Periodontal Index | 1 | 1998 | 10 | 0.040 |
Why?
|
| Bacterial Adhesion | 1 | 1998 | 33 | 0.040 |
Why?
|
| Sphincterotomy, Endoscopic | 1 | 1998 | 79 | 0.040 |
Why?
|
| Therapeutic Irrigation | 1 | 1998 | 63 | 0.040 |
Why?
|
| Magnetics | 1 | 1998 | 52 | 0.040 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 3 | 2005 | 710 | 0.040 |
Why?
|
| Trauma Centers | 1 | 2019 | 197 | 0.040 |
Why?
|
| Infusions, Intra-Arterial | 2 | 2008 | 27 | 0.040 |
Why?
|
| Cold Climate | 1 | 1997 | 2 | 0.040 |
Why?
|
| Body Mass Index | 2 | 1998 | 866 | 0.040 |
Why?
|
| Blood Pressure Determination | 1 | 2018 | 149 | 0.040 |
Why?
|
| Biomarkers, Tumor | 1 | 2001 | 508 | 0.040 |
Why?
|
| Cross-Over Studies | 1 | 1998 | 260 | 0.040 |
Why?
|
| Mortality | 1 | 1998 | 162 | 0.040 |
Why?
|
| Prevalence | 2 | 1999 | 1609 | 0.040 |
Why?
|
| Single-Blind Method | 1 | 2018 | 249 | 0.040 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2017 | 105 | 0.040 |
Why?
|
| Pancreatic Ducts | 1 | 1997 | 76 | 0.040 |
Why?
|
| Transportation of Patients | 1 | 2017 | 46 | 0.040 |
Why?
|
| Europe | 1 | 2017 | 195 | 0.040 |
Why?
|
| Time-to-Treatment | 1 | 2018 | 117 | 0.040 |
Why?
|
| Pattern Recognition, Automated | 1 | 2017 | 70 | 0.040 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 1999 | 626 | 0.040 |
Why?
|
| Toes | 1 | 1996 | 27 | 0.040 |
Why?
|
| Craniotomy | 1 | 1996 | 33 | 0.040 |
Why?
|
| Health Resources | 1 | 2017 | 76 | 0.040 |
Why?
|
| Water | 1 | 1998 | 228 | 0.040 |
Why?
|
| Bupivacaine | 1 | 1996 | 27 | 0.040 |
Why?
|
| Fingers | 1 | 1996 | 39 | 0.040 |
Why?
|
| Cold Temperature | 1 | 1996 | 90 | 0.040 |
Why?
|
| Stomach Neoplasms | 1 | 1997 | 64 | 0.040 |
Why?
|
| Cost Savings | 1 | 2017 | 110 | 0.040 |
Why?
|
| Scalp | 1 | 1996 | 47 | 0.040 |
Why?
|
| Retrospective Studies | 3 | 2010 | 7264 | 0.040 |
Why?
|
| Australia | 1 | 2017 | 235 | 0.040 |
Why?
|
| Students, Medical | 1 | 1998 | 210 | 0.040 |
Why?
|
| Nerve Block | 1 | 1996 | 55 | 0.030 |
Why?
|
| Scleroderma, Systemic | 2 | 1997 | 446 | 0.030 |
Why?
|
| Electrocardiography | 1 | 2018 | 601 | 0.030 |
Why?
|
| Early Medical Intervention | 1 | 2015 | 16 | 0.030 |
Why?
|
| Administration, Intravenous | 1 | 2015 | 89 | 0.030 |
Why?
|
| Basal Metabolism | 1 | 1995 | 22 | 0.030 |
Why?
|
| Phlebitis | 1 | 2014 | 4 | 0.030 |
Why?
|
| American Heart Association | 1 | 2015 | 142 | 0.030 |
Why?
|
| Menstrual Cycle | 1 | 1995 | 64 | 0.030 |
Why?
|
| Injections, Intra-Arterial | 1 | 2014 | 30 | 0.030 |
Why?
|
| Biometry | 1 | 2015 | 72 | 0.030 |
Why?
|
| Child | 4 | 2012 | 6400 | 0.030 |
Why?
|
| Middle Cerebral Artery | 1 | 2014 | 57 | 0.030 |
Why?
|
| Tomography Scanners, X-Ray Computed | 1 | 2014 | 32 | 0.030 |
Why?
|
| Heart Diseases | 2 | 2010 | 276 | 0.030 |
Why?
|
| Software | 1 | 2017 | 418 | 0.030 |
Why?
|
| Propranolol | 1 | 1994 | 102 | 0.030 |
Why?
|
| Testosterone | 1 | 1994 | 96 | 0.030 |
Why?
|
| Injury Severity Score | 1 | 2014 | 204 | 0.030 |
Why?
|
| Stents | 1 | 1998 | 657 | 0.030 |
Why?
|
| Serum Albumin, Human | 1 | 2013 | 10 | 0.030 |
Why?
|
| Radiography | 1 | 2015 | 572 | 0.030 |
Why?
|
| Accidents, Traffic | 1 | 2014 | 109 | 0.030 |
Why?
|
| Organ Size | 1 | 2014 | 242 | 0.030 |
Why?
|
| Acute Coronary Syndrome | 1 | 2015 | 195 | 0.030 |
Why?
|
| Case Management | 1 | 2013 | 46 | 0.030 |
Why?
|
| Costs and Cost Analysis | 1 | 2014 | 193 | 0.030 |
Why?
|
| Diagnostic Imaging | 1 | 2015 | 201 | 0.030 |
Why?
|
| Carotid Artery Diseases | 1 | 2014 | 83 | 0.030 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 2 | 2005 | 137 | 0.030 |
Why?
|
| Estradiol | 1 | 1994 | 176 | 0.030 |
Why?
|
| Heart Failure | 2 | 2015 | 1179 | 0.030 |
Why?
|
| Societies, Medical | 1 | 2015 | 403 | 0.030 |
Why?
|
| Magnetic Resonance Angiography | 1 | 2014 | 181 | 0.030 |
Why?
|
| Pulmonary Embolism | 1 | 2015 | 253 | 0.030 |
Why?
|
| Lymphatic Metastasis | 2 | 2005 | 274 | 0.030 |
Why?
|
| Case-Control Studies | 3 | 2004 | 1548 | 0.030 |
Why?
|
| Atrial Fibrillation | 1 | 2015 | 248 | 0.030 |
Why?
|
| Genotype | 3 | 1999 | 785 | 0.030 |
Why?
|
| Neoplasm Metastasis | 2 | 2005 | 306 | 0.030 |
Why?
|
| Early Termination of Clinical Trials | 1 | 2012 | 11 | 0.030 |
Why?
|
| Neoplasm Staging | 2 | 2005 | 799 | 0.030 |
Why?
|
| Diabetes Complications | 1 | 2014 | 249 | 0.030 |
Why?
|
| Interdisciplinary Communication | 1 | 2012 | 93 | 0.030 |
Why?
|
| Hypnotics and Sedatives | 1 | 2012 | 96 | 0.030 |
Why?
|
| Child, Preschool | 2 | 2012 | 3185 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2013 | 737 | 0.020 |
Why?
|
| Alcoholism | 1 | 1980 | 1109 | 0.020 |
Why?
|
| Troponin | 1 | 2010 | 25 | 0.020 |
Why?
|
| Hypotension | 1 | 2011 | 74 | 0.020 |
Why?
|
| Reperfusion Injury | 1 | 2014 | 320 | 0.020 |
Why?
|
| Hyperhomocysteinemia | 1 | 2010 | 15 | 0.020 |
Why?
|
| Foramen Ovale, Patent | 1 | 2010 | 21 | 0.020 |
Why?
|
| Pregnancy Complications, Cardiovascular | 1 | 2010 | 34 | 0.020 |
Why?
|
| Thrombophilia | 1 | 2010 | 21 | 0.020 |
Why?
|
| Embolism | 1 | 2010 | 45 | 0.020 |
Why?
|
| Cerebral Arteries | 1 | 2010 | 50 | 0.020 |
Why?
|
| Reference Values | 2 | 2004 | 579 | 0.020 |
Why?
|
| Thrombosis | 1 | 2010 | 218 | 0.020 |
Why?
|
| Stress, Psychological | 1 | 1995 | 824 | 0.020 |
Why?
|
| Mental Status Schedule | 1 | 2008 | 31 | 0.020 |
Why?
|
| Hypoglycemic Agents | 1 | 2011 | 361 | 0.020 |
Why?
|
| Insulin | 1 | 2011 | 617 | 0.020 |
Why?
|
| Atherosclerosis | 1 | 2010 | 204 | 0.020 |
Why?
|
| Delayed-Action Preparations | 1 | 2008 | 120 | 0.020 |
Why?
|
| Potassium | 1 | 2008 | 168 | 0.020 |
Why?
|
| Alleles | 2 | 1999 | 386 | 0.020 |
Why?
|
| Neutrophils | 2 | 1999 | 204 | 0.020 |
Why?
|
| Diabetes Mellitus | 2 | 2008 | 693 | 0.020 |
Why?
|
| Vascular Diseases | 1 | 2008 | 94 | 0.020 |
Why?
|
| Patient Dropouts | 1 | 2008 | 98 | 0.020 |
Why?
|
| Factor Analysis, Statistical | 1 | 2008 | 201 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2017 | 2222 | 0.020 |
Why?
|
| Creatinine | 1 | 2008 | 243 | 0.020 |
Why?
|
| Physicians | 1 | 2011 | 324 | 0.020 |
Why?
|
| Anticoagulants | 1 | 2010 | 356 | 0.020 |
Why?
|
| Telephone | 1 | 2008 | 160 | 0.020 |
Why?
|
| Cognition Disorders | 1 | 2010 | 342 | 0.020 |
Why?
|
| Interviews as Topic | 1 | 2008 | 392 | 0.020 |
Why?
|
| Anemia, Sickle Cell | 1 | 2010 | 364 | 0.020 |
Why?
|
| Drug Delivery Systems | 1 | 2008 | 236 | 0.020 |
Why?
|
| Cost of Illness | 1 | 2008 | 204 | 0.020 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2006 | 101 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2008 | 652 | 0.020 |
Why?
|
| Tetrabenazine | 1 | 2005 | 1 | 0.020 |
Why?
|
| Dihydroxyphenylalanine | 1 | 2005 | 13 | 0.020 |
Why?
|
| Fluorine Radioisotopes | 1 | 2005 | 13 | 0.020 |
Why?
|
| Carbon Radioisotopes | 1 | 2005 | 34 | 0.020 |
Why?
|
| Infant | 1 | 2012 | 2891 | 0.020 |
Why?
|
| Biotransformation | 1 | 2005 | 69 | 0.020 |
Why?
|
| Iodine Radioisotopes | 1 | 2005 | 119 | 0.020 |
Why?
|
| Bone Marrow | 1 | 2005 | 168 | 0.020 |
Why?
|
| Receptors, Dopamine | 1 | 2005 | 119 | 0.020 |
Why?
|
| Pregnancy | 1 | 2010 | 2331 | 0.020 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2005 | 81 | 0.020 |
Why?
|
| Axilla | 1 | 2004 | 36 | 0.020 |
Why?
|
| Blood-Brain Barrier | 1 | 2005 | 99 | 0.020 |
Why?
|
| RNA, Neoplasm | 1 | 2004 | 76 | 0.020 |
Why?
|
| Lymph Node Excision | 1 | 2004 | 91 | 0.010 |
Why?
|
| Positron-Emission Tomography | 1 | 2005 | 160 | 0.010 |
Why?
|
| Intelligence | 1 | 1983 | 45 | 0.010 |
Why?
|
| Biopsy, Needle | 1 | 2004 | 191 | 0.010 |
Why?
|
| Forecasting | 1 | 2005 | 277 | 0.010 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2003 | 51 | 0.010 |
Why?
|
| Tomography, Emission-Computed | 1 | 2003 | 40 | 0.010 |
Why?
|
| Hyperparathyroidism | 1 | 2003 | 40 | 0.010 |
Why?
|
| Dopamine | 1 | 2005 | 474 | 0.010 |
Why?
|
| Diagnosis-Related Groups | 1 | 1981 | 28 | 0.010 |
Why?
|
| Computer Systems | 1 | 2001 | 42 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2004 | 1174 | 0.010 |
Why?
|
| Reference Standards | 1 | 2001 | 115 | 0.010 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2001 | 40 | 0.010 |
Why?
|
| DNA, Complementary | 1 | 2001 | 251 | 0.010 |
Why?
|
| DNA Primers | 1 | 2001 | 302 | 0.010 |
Why?
|
| Sex Factors | 2 | 2001 | 1265 | 0.010 |
Why?
|
| Gastrointestinal Diseases | 1 | 2001 | 107 | 0.010 |
Why?
|
| Anemia | 1 | 2001 | 104 | 0.010 |
Why?
|
| ROC Curve | 1 | 2001 | 392 | 0.010 |
Why?
|
| Hawaii | 1 | 1980 | 24 | 0.010 |
Why?
|
| Liver Cirrhosis, Alcoholic | 1 | 1980 | 14 | 0.010 |
Why?
|
| Cocaine | 1 | 2005 | 555 | 0.010 |
Why?
|
| Mouth Mucosa | 1 | 1999 | 51 | 0.010 |
Why?
|
| Base Sequence | 1 | 2001 | 1015 | 0.010 |
Why?
|
| Genetic Markers | 1 | 1999 | 144 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 2 | 1 | 1999 | 14 | 0.010 |
Why?
|
| Substance-Related Disorders | 1 | 2008 | 1241 | 0.010 |
Why?
|
| Neurons | 1 | 2005 | 881 | 0.010 |
Why?
|
| Neutrophil Activation | 1 | 1998 | 3 | 0.010 |
Why?
|
| Polymorphism, Restriction Fragment Length | 1 | 1998 | 44 | 0.010 |
Why?
|
| Homozygote | 1 | 1999 | 119 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 2001 | 1446 | 0.010 |
Why?
|
| Linkage Disequilibrium | 1 | 1998 | 91 | 0.010 |
Why?
|
| Heterozygote | 1 | 1999 | 174 | 0.010 |
Why?
|
| Gene Frequency | 1 | 1998 | 207 | 0.010 |
Why?
|
| Neoplasms | 2 | 1998 | 1660 | 0.010 |
Why?
|
| Dust | 1 | 1997 | 9 | 0.010 |
Why?
|
| Microcirculation | 1 | 1997 | 77 | 0.010 |
Why?
|
| Periosteum | 1 | 1996 | 2 | 0.010 |
Why?
|
| Trochlear Nerve | 1 | 1996 | 3 | 0.010 |
Why?
|
| Isoflurane | 1 | 1996 | 16 | 0.010 |
Why?
|
| Ear, External | 1 | 1996 | 14 | 0.010 |
Why?
|
| Tidal Volume | 1 | 1996 | 17 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2001 | 1663 | 0.010 |
Why?
|
| Anesthetics, Inhalation | 1 | 1996 | 21 | 0.010 |
Why?
|
| Occipital Bone | 1 | 1996 | 11 | 0.010 |
Why?
|
| Skin Temperature | 1 | 1996 | 24 | 0.010 |
Why?
|
| Bone Nails | 1 | 1996 | 32 | 0.010 |
Why?
|
| Age of Onset | 1 | 1997 | 188 | 0.010 |
Why?
|
| Tachycardia | 1 | 1996 | 53 | 0.010 |
Why?
|
| Orbit | 1 | 1996 | 30 | 0.010 |
Why?
|
| Regional Blood Flow | 1 | 1996 | 168 | 0.010 |
Why?
|
| Temporal Bone | 1 | 1996 | 53 | 0.010 |
Why?
|
| Intracranial Pressure | 1 | 1996 | 58 | 0.010 |
Why?
|
| Pressure | 1 | 1997 | 252 | 0.010 |
Why?
|
| Systole | 1 | 1996 | 149 | 0.010 |
Why?
|
| Blood Vessels | 1 | 1996 | 102 | 0.010 |
Why?
|
| Manometry | 1 | 1997 | 276 | 0.010 |
Why?
|
| Chi-Square Distribution | 1 | 1997 | 546 | 0.010 |
Why?
|
| Activities of Daily Living | 1 | 1997 | 319 | 0.010 |
Why?
|
| Environmental Pollutants | 1 | 1997 | 180 | 0.010 |
Why?
|
| Genetic Predisposition to Disease | 1 | 1998 | 785 | 0.010 |
Why?
|
| Metabolic Clearance Rate | 1 | 1994 | 48 | 0.010 |
Why?
|
| Lactates | 1 | 1994 | 29 | 0.010 |
Why?
|
| Heart Rate | 1 | 1996 | 568 | 0.010 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 1994 | 381 | 0.010 |
Why?
|
| Endoscopy | 1 | 1997 | 464 | 0.010 |
Why?
|
| Life Style | 1 | 1995 | 338 | 0.010 |
Why?
|
| Diagnosis, Differential | 1 | 1996 | 1139 | 0.010 |
Why?
|
| Incidence | 1 | 1997 | 1582 | 0.010 |
Why?
|
| Oxidation-Reduction | 1 | 1994 | 567 | 0.010 |
Why?
|
| Surveys and Questionnaires | 1 | 1997 | 2798 | 0.010 |
Why?
|
| Epidemiologic Methods | 1 | 1982 | 83 | 0.000 |
Why?
|